KR20200054232A - 트라디피탄트를 이용한 아토피 피부염의 개선된 치료 - Google Patents

트라디피탄트를 이용한 아토피 피부염의 개선된 치료 Download PDF

Info

Publication number
KR20200054232A
KR20200054232A KR1020207010029A KR20207010029A KR20200054232A KR 20200054232 A KR20200054232 A KR 20200054232A KR 1020207010029 A KR1020207010029 A KR 1020207010029A KR 20207010029 A KR20207010029 A KR 20207010029A KR 20200054232 A KR20200054232 A KR 20200054232A
Authority
KR
South Korea
Prior art keywords
patient
tradipitant
genotype
treatment
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207010029A
Other languages
English (en)
Korean (ko)
Inventor
미하엘 에이치. 폴리머로풀로스
창푸 시아오
군터 버즈니엑스
앤드류 하이트만
산드라 스미스젝
Original Assignee
반다 파마슈티칼즈, 인코퍼레이티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 반다 파마슈티칼즈, 인코퍼레이티드. filed Critical 반다 파마슈티칼즈, 인코퍼레이티드.
Priority to KR1020257006413A priority Critical patent/KR20250036264A/ko
Publication of KR20200054232A publication Critical patent/KR20200054232A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Physical Education & Sports Medicine (AREA)
KR1020207010029A 2017-09-13 2018-08-30 트라디피탄트를 이용한 아토피 피부염의 개선된 치료 Ceased KR20200054232A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257006413A KR20250036264A (ko) 2017-09-13 2018-08-30 트라디피탄트를 이용한 아토피 피부염의 개선된 치료

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762558303P 2017-09-13 2017-09-13
US62/558,303 2017-09-13
US201762572456P 2017-10-14 2017-10-14
US62/572,456 2017-10-14
PCT/US2018/048825 WO2019055225A1 (en) 2017-09-13 2018-08-30 ENHANCED TREATMENT OF ATOPIC DERMATITIS USING TRADIPITANT

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257006413A Division KR20250036264A (ko) 2017-09-13 2018-08-30 트라디피탄트를 이용한 아토피 피부염의 개선된 치료

Publications (1)

Publication Number Publication Date
KR20200054232A true KR20200054232A (ko) 2020-05-19

Family

ID=63684468

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207010029A Ceased KR20200054232A (ko) 2017-09-13 2018-08-30 트라디피탄트를 이용한 아토피 피부염의 개선된 치료
KR1020257006413A Pending KR20250036264A (ko) 2017-09-13 2018-08-30 트라디피탄트를 이용한 아토피 피부염의 개선된 치료

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257006413A Pending KR20250036264A (ko) 2017-09-13 2018-08-30 트라디피탄트를 이용한 아토피 피부염의 개선된 치료

Country Status (11)

Country Link
US (1) US11549147B2 (https=)
EP (2) EP4487912A3 (https=)
JP (1) JP7347743B2 (https=)
KR (2) KR20200054232A (https=)
CN (1) CN111093671A (https=)
AU (1) AU2018331267B2 (https=)
CA (1) CA3073998A1 (https=)
CL (1) CL2020000655A1 (https=)
IL (1) IL272949B2 (https=)
MX (2) MX2020002852A (https=)
WO (1) WO2019055225A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021225303A1 (ko) 2020-05-07 2021-11-11 주식회사 엘지에너지솔루션 고-니켈 전극 시트 및 이의 제조방법

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2978736C (en) 2015-03-04 2023-11-07 Vanda Pharmaceuticals Inc. Dosing regimen of tradipitant
CN112218636B (zh) 2018-06-08 2025-05-06 万达制药公司 使用川地匹坦进行治疗的方法
JP2023515167A (ja) * 2020-02-25 2023-04-12 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによるアトピー性皮膚炎の改善された治療
WO2021195205A1 (en) 2020-03-26 2021-09-30 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
CN120641099A (zh) 2022-12-21 2025-09-12 万达制药公司 使用曲地匹坦的治疗方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW263498B (https=) 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
KR100755577B1 (ko) 2002-04-26 2007-09-12 일라이 릴리 앤드 캄파니 타키키닌 수용체 길항제로서의 트리아졸 유도체
BR0309486A (pt) 2002-04-26 2005-02-09 Lilly Co Eli Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas
JP2004250329A (ja) 2002-12-26 2004-09-09 Dainippon Pharmaceut Co Ltd イサチン誘導体
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
NZ580480A (en) 2003-10-24 2010-02-26 Lilly Co Eli Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
JP4673068B2 (ja) 2005-01-19 2011-04-20 独立行政法人科学技術振興機構 Ｔｈ１型アレルギー疾患治療用組成物
DE102005006217B4 (de) 2005-02-07 2007-08-16 Universitätsklinikum Hamburg-Eppendorf Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum
WO2007096782A2 (en) 2006-02-22 2007-08-30 Valorisation Recherche Hscm, Limited Partnership Compositions for disorders associated wtth metachromatic cell activation
CN101568523A (zh) 2006-12-20 2009-10-28 伊莱利利公司 用于制备{2-[1-(3,5-二-三氟甲基-苄基)-5-吡啶-4-基-1h-[1,2,3]三唑-4-基]－吡啶－3－基｝·(2－氯苯基)甲酮的新中间体和方法
JP6644328B2 (ja) 2013-02-28 2020-02-12 ロート製薬株式会社 アトピー性疾患の発症又は重症化リスクの評価法
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
BR112015031724A2 (pt) 2013-06-24 2017-07-25 Tigercat Pharma Inc uso do antagonista do receptor nk-1 serlopitant em pruridos
CA2978736C (en) 2015-03-04 2023-11-07 Vanda Pharmaceuticals Inc. Dosing regimen of tradipitant
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021225303A1 (ko) 2020-05-07 2021-11-11 주식회사 엘지에너지솔루션 고-니켈 전극 시트 및 이의 제조방법

Also Published As

Publication number Publication date
AU2018331267A1 (en) 2020-04-16
EP4487912A3 (en) 2025-03-26
MX2024004377A (es) 2024-04-26
WO2019055225A1 (en) 2019-03-21
MX2020002852A (es) 2020-07-22
CN111093671A (zh) 2020-05-01
EP3681505C0 (en) 2024-12-18
AU2018331267B2 (en) 2024-03-07
EP3681505B1 (en) 2024-12-18
CA3073998A1 (en) 2019-03-21
CL2020000655A1 (es) 2020-10-09
IL272949B2 (en) 2025-07-01
IL272949B1 (en) 2025-03-01
IL272949A (en) 2020-04-30
JP7347743B2 (ja) 2023-09-20
JP2020533381A (ja) 2020-11-19
EP4487912A2 (en) 2025-01-08
US20210062262A1 (en) 2021-03-04
RU2020112222A (ru) 2021-10-13
US11549147B2 (en) 2023-01-10
BR112020004964A2 (pt) 2020-09-15
EP3681505A1 (en) 2020-07-22
KR20250036264A (ko) 2025-03-13

Similar Documents

Publication Publication Date Title
EP3681505B1 (en) Improved treatment of atopic dermatitis with tradipitant
Yoshida et al. Skin barrier defects in atopic dermatitis: from old idea to new opportunity
Martin et al. Stimulator of interferon genes (STING) activation exacerbates experimental colitis in mice
Horak et al. The CRTH 2 antagonist OC 000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo‐controlled, double‐blind trial
US12318375B2 (en) Method of treatment with tradipitant
Banno et al. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy
Neighbour et al. Safety and efficacy of an oral CCR 3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placebo‐controlled clinical trial
Montuschi et al. Leukotriene modifiers for asthma treatment
Zellweger et al. IgE‐associated allergic disorders: recent advances in etiology, diagnosis, and treatment
EP4005570B1 (en) Pridopidine for use in treating rett syndrome
JP6502863B2 (ja) 結腸直腸癌を処置する方法
Clark et al. Intranasal neuropeptide Y1 receptor antagonism improves motor deficits in symptomatic SOD1 ALS mice
Wang et al. Suppression of eEF2 phosphorylation alleviates synaptic failure and cognitive deficits in mouse models of Down syndrome
Ge et al. Stress aggravates imiquimod-induced psoriasiform inflammation by promoting M1 macrophage polarization
Amoruso et al. Neurokinin (NK)-1 receptor expression in monocytes from bipolar disorder patients: A pilot study
US20230073637A1 (en) Treatment of atopic dermatitis with tradipitant
Wang et al. Associations among angiotensin-converting enzyme, neuroinflammation, and cerebrospinal fluid biomarkers of Alzheimer's disease in non-dementia adults
RU2812890C2 (ru) Усовершенствованное лечение атопического дерматита традипитантом
RU2793237C2 (ru) Усовершенствованное лечение атопического дерматита традипитантом
BR112020004964B1 (pt) Método para determinar uma dose eficaz de tradipitant ou um sal farmaceuticamente aceitável do mesmo
Spears et al. Factors influencing individual variability in the therapeutic response to corticosteroids in asthma
JP7812535B2 (ja) 新型コロナウイルス感染症後遺症治療薬のスクリーニング方法及び新型コロナウイルス感染症後遺症モデル動物の製造方法
Liao et al. Calprotectin Is a Circulating Biomarker and Potential Therapeutic Target for Sarcopenia in Chronic Obstructive Pulmonary Disease
Thomson Anti-Mediator Therapy

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104